THE DUFFY ANTIGEN RECEPTOR FOR CHEMOKINES (DARC) IN ACUTE POST-ISCHEMIC RENAL FAILURE (APRF) - A CONDUCTOR OF RENAL CHEMOKINE PRESENTATION.

2005 ◽  
Vol 33 ◽  
pp. A139
Author(s):  
Kai Singbartl ◽  
Alexander Zarbock ◽  
Mirco Schmolke ◽  
Marion Scharte ◽  
Hugo Van Aken
2004 ◽  
Vol 32 (Supplement) ◽  
pp. A131
Author(s):  
Kai Singbartl ◽  
Susanne grosse Bockhorn ◽  
Hugo Van Aken

2007 ◽  
Vol 35 (9) ◽  
pp. 2156-2163 ◽  
Author(s):  
Alexander Zarbock ◽  
Mirco Schmolke ◽  
Susanne Groe Bockhorn ◽  
Marion Scharte ◽  
Kirsten Buschmann ◽  
...  

VASA ◽  
2014 ◽  
Vol 43 (1) ◽  
pp. 47-54 ◽  
Author(s):  
Weibin Huang ◽  
Weiwei Qin ◽  
Lei Lv ◽  
Haoyv Deng ◽  
Hao Zhang ◽  
...  

Background: Duffy antigen / receptor for chemokines (DARC) possesses high affinity for several chemokine subgroups of CC and CXC. Although DARC has been shown to play a role in many inflammatory diseases, its effect on chronic venous disease (CVD) remains unidentified. We explored whether the expression of DARC in skin tissue was activated under venous hypertension as well as the relationships between DARC and inflammation. Materials and methods: The inflammation in a rat model of venous hypertension caused by a femoral arterial-venous fistula (AVF) was studied. At specified intervals the pressure in the femoral veins was recorded within 42 days. Hindlimb skin specimens were harvested at different time points. The expressions of DARC, interleukin-8 (IL-8), and monocyte chemotactic protein-1 (MCP-1) in skin tissue were examined. Mononuclear cells infiltrated in skin tissue were detected. Results: Femoral venous pressures in AVF groups increased significantly at different time points (P < 0.01). DARC was expressed in skin tissue and its expression level increased significantly in AVF groups from the 7nd day on and was enhanced in a time-dependent manner within 42 days (P < 0.05). Meanwhile, both MCP-1 and IL-8 had higher levels, accompanied by increased mononuclear cells infiltrating into skin tissue (P < 0.05). Conclusions: A rat AVF model which can maintain venous hypertension for at least 42 days is competent for researching the pathogenesis of CVD. DARC, which plays a role in the inflammation of skin tissue under venous hypertension, may become a new molecular target for diagnosis and treatment of CVD at a very early stage.


2017 ◽  
Vol 47 (9) ◽  
pp. 1214-1222 ◽  
Author(s):  
D. G. Chapman ◽  
E. B. Mougey ◽  
J. L. Van der Velden ◽  
K. G. Lahue ◽  
M. Aliyeva ◽  
...  

1985 ◽  
Vol 248 (3) ◽  
pp. F340-F346 ◽  
Author(s):  
J. E. Hall ◽  
J. P. Granger ◽  
R. L. Hester

This study examined interactions between adenosine (Ado) and angiotensin II (ANG II) in controlling renal blood flow (RBF) and glomerular filtration rate (GFR). In six normal dogs, intrarenal Ado infusion (1.0 mumol/min) transiently decreased RBF, but during sustained Ado infusion RBF increased to 122 +/- 7% of control, although GFR remained at 75 +/- 6% of control. Blockade of ANG II formation with the converting enzyme inhibitor SQ 14225 (n = 6) almost abolished the transient decrease in RBF but did not prevent the sustained fall in GFR caused by Ado. When circulating ANG II was held constant by intravenous infusion of SQ 14225 and 20 ng . kg-1 . min-1 of ANG II (n = 6), Ado transiently decreased RBF but the return of RBF was much slower than in normal dogs and RBF did not increase above control. Maintenance of constant circulating ANG II did not prevent Ado-mediated decreases in GFR. These observations suggest that Ado-mediated reductions in GFR do not depend entirely on ANG II and may be due to dilation of efferent arterioles by Ado. However, the transient renal vasoconstriction caused by Ado depends on ANG II, and data from this study suggest that part of the waning constrictor response to Ado is due to suppression of renin secretion and endogenous ANG II formation. In circumstances where high ANG II levels are maintained (i.e., ischemic renal failure), Ado may be capable of causing sustained renal vasoconstriction.


1991 ◽  
Vol 69 (21-23) ◽  
pp. 1083-1094 ◽  
Author(s):  
H. J. Schiller ◽  
K. A. Andreoni ◽  
G. B. Bulkley

Author(s):  
Pietro Zucchelli ◽  
Alessandro Zuccal�

Sign in / Sign up

Export Citation Format

Share Document